Comparison of Hemorrhagic Risk between Prasugrel and Clopidogrel: a Retrospective Study using Adverse Drug Event Reporting Databases

Background: Prasugrel inhibits platelet aggregation more potently and exerts therapeutic action faster than clopidogrel. In the global phase III trial conducted in Western and South American countries that excluded Asian countries, prasugrel reduced ischemic events but increased hemorrhagic risk com...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagiwara, Hiromi, Fukuta, Hidekatsu, Niimura, Takahiro, Zamami, Yoshito, Ishizawa, Keisuke, Kimura, Kazunori, Kamiya, Takeshi, Ohte, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7085259/
https://www.ncbi.nlm.nih.gov/pubmed/32218694
http://dx.doi.org/10.7150/ijms.43168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7085259/
https://www.ncbi.nlm.nih.gov/pubmed/32218694
http://dx.doi.org/10.7150/ijms.43168

Ejemplares similares